Mimedx (MDXG) Accounts Payables (2010 - 2026)
Mimedx recorded quarterly Accounts Payables of $11.5 million in Q1 2026, down 21.09% quarter-over-quarter from $14.5 million in Q4 2025, and up 29.27% year-over-year from $8.9 million in Q1 2025.
Mimedx's Accounts Payables history runs 17 years deep, the most recent figure standing at $11.5 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 29.27% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $11.5 million (up 29.27% YoY), while the FY2025 annual figure was $14.5 million, up 96.09% from the prior year.
- Accounts Payables came in at $11.5 million for Q1 2026 at Mimedx, down from $14.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $14.5 million in Q4 2025 to a low of $6.9 million in Q3 2024.
- A 5-year average of $9.1 million and a median of $8.5 million in 2025 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables retreated 24.49% in 2024 and soared 96.09% in 2025, its largest moves.
- Mimedx's Accounts Payables stood at $8.5 million in 2022, then grew by 7.03% to $9.0 million in 2023, then retreated by 18.11% to $7.4 million in 2024, then jumped by 96.09% to $14.5 million in 2025, then slipped by 21.09% to $11.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $11.5 million, $14.5 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.46 Mn |
| Dec 31, 2025 | 14.53 Mn |
| Sep 30, 2025 | 11.42 Mn |
| Jun 30, 2025 | 8.50 Mn |
| Mar 31, 2025 | 8.87 Mn |
| Dec 31, 2024 | 7.41 Mn |
| Sep 30, 2024 | 6.92 Mn |
| Jun 30, 2024 | 7.60 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | 9.05 Mn |
| Sep 30, 2023 | 9.17 Mn |
| Jun 30, 2023 | 8.15 Mn |
| Mar 31, 2023 | 7.82 Mn |
| Dec 31, 2022 | 8.45 Mn |
| Sep 30, 2022 | 8.82 Mn |
| Jun 30, 2022 | 8.08 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 7.39 Mn |
| Sep 30, 2021 | 6.88 Mn |
| Jun 30, 2021 | 10.56 Mn |
| Mar 31, 2021 | 6.93 Mn |
| Dec 31, 2020 | 8.77 Mn |
| Sep 30, 2020 | 9.05 Mn |
| Jun 30, 2020 | 11.95 Mn |
| Mar 31, 2020 | 9.76 Mn |
| Dec 31, 2019 | 8.71 Mn |
| Sep 30, 2019 | 9.42 Mn |
| Jun 30, 2019 | 10.79 Mn |
| Mar 31, 2019 | 10.69 Mn |
| Dec 31, 2018 | 14.86 Mn |
| Dec 31, 2017 | 8.45 Mn |
| Sep 30, 2017 | 8.77 Mn |
| Jun 30, 2017 | 11.50 Mn |
| Mar 31, 2017 | 10.89 Mn |
| Dec 31, 2016 | 12.41 Mn |
| Sep 30, 2016 | 11.16 Mn |
| Jun 30, 2016 | 9.68 Mn |
| Mar 31, 2016 | 13.06 Mn |
| Dec 31, 2015 | 6.63 Mn |
| Sep 30, 2015 | 7.24 Mn |
| Jun 30, 2015 | 5.61 Mn |
| Mar 31, 2015 | 5.38 Mn |
| Dec 31, 2014 | 3.66 Mn |
| Sep 30, 2014 | 2.76 Mn |
| Jun 30, 2014 | 2.45 Mn |
| Mar 31, 2014 | 2.62 Mn |
| Dec 31, 2013 | 2.49 Mn |
| Sep 30, 2013 | 2.21 Mn |
| Jun 30, 2013 | 1.84 Mn |
| Mar 31, 2013 | 1.06 Mn |
| Dec 31, 2012 | 1.25 Mn |
| Sep 30, 2012 | 3.75 Mn |
| Jun 30, 2012 | 1.90 Mn |
| Mar 31, 2012 | 1.83 Mn |
| Dec 31, 2011 | 1.52 Mn |
| Sep 30, 2011 | 1.88 Mn |
| Jun 30, 2011 | 1.62 Mn |
| Dec 31, 2010 | 848,285.00 |